289 results
8-K
EX-99.1
BIIB
Biogen Inc
24 Apr 24
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
7:02am
litigation, as all are hard to predict, or any impact of potential tax or healthcare reform. Biogen may incur charges, realize gains or losses, or experience … of pending or future significant litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material
8-K
EX-99.1
8oee ooi6ht23
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
8-K
EX-3.2
0ae2p7a
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-3.1
xheibqh6pfgq6k
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-99.1
i9cm0xrgrgho i22w
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K
941pt
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-10.1
nbggjiexr6
1 Sep 23
Entry into a Material Definitive Agreement
4:36pm
DEFA14A
6bh7t1d
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
chri ddjh
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.2
idz2de
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.3
qm3cjm
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-2.1
53ia0ewwhfn56tse2
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-3.1
wlf60 9dlj4mz7rmm83
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
g968ft
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
DEFA14A
rgc9xiihc
28 Jul 23
Additional proxy soliciting materials
7:13am